NASDAQ : ABCL
AbCellera Biologics Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 12.27 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.98B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.60B |
| Enterprise Value | 3.20B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 324.05M |
| Shares Outstanding | 324.05M |
| Shares Change (YoY) | +1.74% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 21.64% |
| Owned by Institutions (%) | 26.23% |
| Float | 220.93M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 54.46 |
| Forward PS | 99.70 |
| PB Ratio | 3.80 |
| P/TBV Ratio | 4.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 48.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.77 |
| Quick Ratio | 11.23 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -17.30% |
| Return on Assets (ROA) | -10.39% |
| Return on Invested Capital (ROIC) | -42.28% |
| Return on Capital Employed (ROCE) | -17.95% |
| Weighted Average Cost of Capital (WACC) | 11.57% |
| Revenue Per Employee | $117,740 |
| Profits Per Employee | -$292,982 |
| Employee Count | 562 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -32.11M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.41 |
| 52-Week Price Change | +100.36% |
| 50-Day Moving Average | 12.28 |
| 200-Day Moving Average | 6.89 |
| Relative Strength Index (RSI) | 41.49 |
| Average Volume (20 Days) | 4,344,126 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 30.93M |
| Short Previous Month | 32.50M |
| Short % of Shares Out | 9.55% |
| Short % of Float | 14.00% |
| Short Ratio (days to cover) | 5.65 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 66.17M |
| Gross Profit | -131.60M |
| Operating Income | -225.16M |
| Pretax Income | -196.77M |
| Net Income | -164.66M |
| EBITDA | -199.96M |
| EBIT | -225.16M |
| Loss Per Share | -$0.55 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 540.10M |
| Total Debt | 135.62M |
| Net Cash | 404.49M |
| Net Cash Per Share | $1.25 |
| Equity (Book Value) | 896.02M |
| Book Value Per Share | 2.92 |
| Working Capital | 626.04M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -94.94M |
| Capital Expenditures | -24.73M |
| Depreciation & Amortization | 25.20M |
| Net Borrowing | 29.73M |
| Free Cash Flow | -119.67M |
| FCF Per Share | -$0.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | -198.88% |
| Operating Margin | -340.27% |
| Pretax Margin | -297.37% |
| Profit Margin | -248.84% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.74% |
| Shareholder Yield | -1.74% |
| Earnings Yield | -4.91% |
| FCF Yield | -3.32% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.17 |
| Price Target Difference | 54.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | -27.14% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.83 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |